| Document |
Document Title |
|
JP2017178795A |
To provide a new compound exhibiting charge transporting capacity used for an electrophotographic photoreceptor and the like.The compound has a structure represented by general formula (C1). (Rto R, Rto R, and Rto Rare each independently...
|
|
JP6187980B2 |
|
|
JP2017515900A |
Provided herein are compounds of (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and It is a prodrug. Also provided are compounds of the invention for the treatment ...
|
|
JP6080281B1 |
[Subject] An object of the present invention is to provide a method that oxidation reaction output of the hydrocarbon or its derivative can be manufactured efficiently by using hydrocarbon or its derivative as materials. [Means for Solut...
|
|
JPWO2014103321A1 |
To provide a novel pyruvate dehydrogenase inhibitor. A pyruvate dehydrogenase inhibitor containing a compound represented by the general formula (I) as an active ingredient (in the formula, ring A has aromaticity which may be substituted...
|
|
JP2017001971A |
To provide a method for suppressing polymerization of aromatic vinyl monomers having enhanced polymerization suppression effect.There is provided a method for suppressing polymerization of aromatic vinyl monomers including adding α-hydr...
|
|
JP2017001970A |
To provide a method for suppressing polymerization of aromatic vinyl monomers having enhanced polymerization suppression effect.There is provided a method for suppressing polymerization of aromatic vinyl monomers including adding a compo...
|
|
JP2016225431A |
To provide a photovoltaic element in which charge separation is easily caused and charge recombination is hardly caused.A photovoltaic element contains a compound having a charge separation action. The compound includes an electron-donat...
|
|
JP5969616B2 |
The present invention is: a guest-compound-enveloping polymer-metal-complex crystal characterized by at least one selected from an aliphatic hydrocarbon, an alicyclic hydrocarbon, an ether, an ester, an aromatic hydrocarbon, a halogenate...
|
|
JP5917458B2 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KS...
|
|
JP2016065056A |
To provide compositions for treating at least one of the local conditions associated with aging, acne, topical bacterial infections, topical fungal infections, and topical viral infections.Provided is a composition comprising at least tw...
|
|
JP2016047854A |
To provide a method for treating a mitochondrial disorder, adjusting one or more energy biomarkers, normalizing one or more energy biomarkers, or strengthening one or more energy biomarkers.Disclosed are not only the treatment method or ...
|
|
JP2016034979A |
To provide (hetero)aryl-p-quinone derivatives for treatment of mitochondrial diseases.Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondria...
|
|
JP2016029112A |
To provide effective methods of treating mitochondrial disorders, such as: Friedreich's ataxia; Leber's hereditary optic neuropathy; mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes (MELAS); and Kearns-Sayr...
|
|
JP5860722B2 |
An high mobility structured organic film comprising a plurality of segments and a plurality of linkers arranged as a covalent organic framework, wherein the structured organic film may be a multi-segment thick structured organic film.
|
|
JP2015533794A |
One or more energies to treat or suppress oxidative stress disorders, including mitochondrial disorders, hypoenergy processing disorders, neurodegenerative diseases and aging disorders, or to modulate one or more energy biomarkers Compou...
|
|
JP2015531404A |
Vitamin K2The MK-7 type preparation method is characterized by the addition of a hexaprenyl chain in the "whole trans" configuration to the monoprenyl derivative of menadiol by the "1 + 6" strategy. According to the present invention, in...
|
|
JP2015187169A |
To provide processes for production, enrichment and/or isolation of pure α-tocotrienol.The invention discloses novel processes for production, enrichment and/or isolation of α-tocotrienol from a raw material source comprising at least ...
|
|
JP2015168660A |
To produce arylhydroquinones and arylquinones in mild conditions without using a rare metal catalyst.A method for producing arylhydroquinones by Michael addition of a an aryl compound with quinones in the presence of a catalyst. As the c...
|
|
JP2015527322A |
Rain analogs that exhibit antiproliferative activity, especially against cancer cells, are described herein. In some embodiments, the compound contains a flat or planar ring system. Such a ring works by promoting non-covalent binding of ...
|
|
JP5775459B2 |
The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
|
|
JP5748660B2 |
The present invention relates to polymers comprising repeating unit(s) of the formula (I), and their use in electronic devices. The polymers according to the invention have excellent solubility in organic solvents and excellent film-form...
|
|
JP5725299B2 |
1,4 naphthoquinones derivatives, of formula (I) wherein A is selected from the following rings: their preparation and their application as antimalarial agents
|
|
JPWO2013121873A1 |
The method for producing a biaryl compound of the present invention includes a step of reacting phenol or naphthol in the presence of tetrabutylammonium iodide and tert-butyl hydroperoxide or hydrogen peroxide. [Chemical 1]
|
|
JP2015078224A |
To provide a compound useful for therapy or suppression of diseases due to mitochondrial diseases and for adjustment of an energy biomarker in a subject.A method of treating a mitochondrial disease, adjusting 1 or more energy biomarkers,...
|
|
JP2015010050A |
To provide a production method for producing a valuable product using lignin in which an effective utilization method development thereof is required without using expensive, or special facilities, agents, and processes.Hydrogen peroxide...
|
|
JP5649454B2 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS),...
|
|
JP5641582B2 |
|
|
JP2014530190A |
Provided is a method for effectively and efficiently oxidizing an alkyl-containing molecule using an oxygen-containing gas. An iridium metal catalyst complex in which a nitrogen atom of a benzimidazolyl-containing ligand is coordinated w...
|
|
JP2014189486A |
To provide an oxidizer for efficient production of 1,4-benzoquinone compounds which are quite useful as synthetic intermediates for medicines and agrochemicals.1,4-Benzoquinone compounds of formula (A) are produced from corresponding alk...
|
|
JP2014189487A |
To provide a method for efficiently producing a 1,4-benzoquinone compound which is extremely useful as a synthetic intermediate of a medicine or an agrochemical or the like.There is produced corresponding 1,4-benzoquinones by oxidation w...
|
|
JP5597924B2 |
Disclosed is a polyarylene copolymer containing a sulfonic acid group, which has high proton conductivity and excellent methanol resistance. Also disclosed are a solid polymer electrolyte and a proton conducting membrane, each is made of...
|
|
JP2014169334A |
To provide effective methods of treating mitochondrial damage, such as: Friedreich's ataxia; Leber's hereditary optic neuropath; myopathy, encephalopathy, lactic acidosis and stroke-like episode (MELAS); and Kearns-Sayre syndrome.The pre...
|
|
JP2014520894A |
A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing a...
|
|
JP5575350B2 |
OLED materials are provided that have the general formula:wherein the subscript n is an integer of from 5 to 15; the superscript i is an integer of from 1 to n and denotes the position downstream from R<1>; each Aris a substituted or uns...
|
|
JP5567499B2 |
[Problem] To provide an antioxidant which has an effective antioxidant effect without showing any side effects. [Solution] A novel substance represented by formula (1).
|
|
JP5524043B2 |
The invention relates to a process of preparing substituted pentacenes, to novel pentacenes prepared by this process, to the use of the novel pentacenes as semiconductors or charge transport materials in optical, electrooptical or electr...
|
|
JP2014080578A |
To provide a coloring composition that exhibits a high color value and excellent heat and light resistance; and a photosensitive coloring composition.A coloring composition contains: a phthalocyanine compound (A) represented by the speci...
|
|
JP2014510698A |
Disclosed herein is novel process for preparation of atovaquone, which process includes reacting 1H-2-benzopyran-1,4(3H)-dione with 4-(4-chlorophenyl)cyclohexanecarbaldehyde. The invention further discloses novel intermediates useful in ...
|
|
JP5479175B2 |
The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represente...
|
|
JP2014058569A |
To provide a (hetero)aryl-p-quinone derivative for a treatment of mitochondrial diseases.Methods of treating or inhibiting mitochondrial diseases, for example friedreich ataxia (FRDA), Leber's hereditary optic neuropathy (LHON), mitochon...
|
|
JP2014051432A |
To provide an anthraquinone composition having stability to reduction, oxidation and hydrolysis in producing hydrogen peroxide by an anthraquinone method, high solubility to an organic solvent, and further preferably used as a medium sup...
|
|
JP5442977B2 |
|
|
JP5441668B2 |
|
|
JP5424613B2 |
Stabilizing olefinically unsaturated monomer comprises adding a retarder containing composition (I), where (I) comprises a solvent (A) from optionally saturated, ring closed and/or open chain aliphatic or aromatic 4-20C-hydrocarbons, -et...
|
|
JP5417708B2 |
|
|
JP5374162B2 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KS...
|
|
JP5362759B2 |
A mixture contains a matrix material containing specified units; and a material which is capable of emission and which contains an element of atomic number above 20. A mixture contains (a) a matrix material containing units of formula C:...
|
|
JP5364372B2 |
A process for the preparation of ubihydroquinones and ubiquinones by condensation of a prenol or isoprenol with a hydroquinone or derivative thereof in the presence of 0.005-1.0 mol % of a catalyst which is a Broensted-acid, a Lewis-acid...
|
|
JP5339040B2 |
To provide a novel anticancer drug that has an activity of inhibiting cell growth, and moreover, is effective even to a cancer cell having acquired resistance, and a novel compound suitable therefor. The novel naphthoquinone compound is ...
|
